undamentalytics Newsletter
Sign in

Cytomed Therapeutics Ltd cash flow statement

In fiscal 2025, Cytomed Therapeutics Ltd's operations generated −$2.8m of cash; it spent $488,404 on capital projects, leaving free cash flow of −$3.3m.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025
Cash from operations−2,028−2,831
Depreciation and amortisation923
Stock-based pay—532
Capital spending1,048488
Free cash flow−3,076−3,320
Free cash flow after stock pay—−3,851

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CLNN vs GDTCCRVO vs GDTCCLDX vs GDTC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cytomed Therapeutics Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cytomed Therapeutics Ltd.